Clinical trial
Rivaroxaban Versus Vitamin K-Antagonist (VKA) in Thromboprophylaxis of Patients With Atrial Fibrillation: Patient Preference Study
NCT02090543 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Rivaroxaban Versus Vitamin K-Antagonist (VKA) in Thromboprophylaxis of Patients With Atrial Fibrillation: Patient Preference Study
- Lead sponsor
- Bayer
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 31, 2014
- Completion date
- October 31, 2014
- Enrollment
- 647 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.